Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk Makes Case For Alogliptin-Shadowed Victoza

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo hopes the differing drug class and bigger Phase III trial will help diabetes drug get past heart-safety rules that tripped up the compound from Takeda.

You may also be interested in...



Merck Bolsters Januvia Access With Outcomes-Based Discounts To CIGNA

Merck will provide CIGNA with price discounts on Januvia and Janumet that are tied to member outcomes - lower blood sugar and medication adherence - in a novel contract arrangement announced by CIGNA April 23

Saxagliptin Review Deadline Pushed Back; Approval Chances Still Look Good

FDA is extending the user fee goal date for action on Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor antidiabetic Onglyza (saxagliptin) to July 30

Merck Bolsters Januvia Access With Outcomes-Based Discounts To CIGNA

Merck will provide CIGNA with price discounts on Januvia and Janumet that are tied to member outcomes - lower blood sugar and medication adherence - in a novel contract arrangement announced by CIGNA April 23

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel